9 results
Objective of the ANKLE TRIAL is to differentiate between results of three types of functional treatment in a profound methodological way, with primary research question: what will be the optimal functional treatment for acute lateral ankle ligament…
With this trial we want to compare both somatostatin analogues, octreotide and lanreotide, in one trial, so we can see whether there is a difference in effect on liver volume in patients with polycystic livers. Furthermore, we want to find the…
Objective of the ANKLE TRIAL is to differentiate between results of three types of functional treatment in a profound methodological way, with primary research question: what will be the optimal functional treatment for acute lateral ankle ligament…
To assess the efficacy of the co-administration of lanreotide Autogel 120 mg(administered via deep sub-cutaneous injections every 28 days) and pegvisomant(administered at 40 to 120 mg per week via sub-cutaneous injection given once ortwice a week)…
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…
To evaluate the safety and efficacy of multiple doses of ABT-494 (Upadacitinib) monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis.
To investigate the efficacy of lanreotide therapy as compared to placebo in patients with NFMA and positive pituitary somatostatin receptor imaging using Gallium-68 DOTATATE PET/CT, on tumor size.
To assess long-term safety, tolerability and efficacy of upadacitinib in adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study. Efficacy will be evaluated through Week 52, and safety and…
The objectives of this study, in patients with moderately to severely active UC who are administered JAKi SOC therapy are to evaluate the following (ranked according to priority), both for JAKi as a class of drugs and for each individual JAKi:1.…